Business
Personalis Reports First Quarter Results and Recent Highlights
FREMONT, Calif., May 07, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent business accomplishments, and reaffirmed financial guidance for the full year 2026.
About this update from Personalis, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6531bb76fa21b32c077d5d13c3634a24"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pAjr1z2GiCFZgJ7JH6TJWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/6531bb76fa21b32c077d5d13c3634a24","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/iR2g98Ch817hYE2COWjskw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/6531bb76fa21b32c077d5d13c3634a24","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gB9.kVexVuXYirCnu8j1cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/6531bb76fa21b32c077d5d13c3634a24","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"Medicare coverage secured for lung cancer surveillance, providing a clear path to monetize rapidly growing clinical test volumes","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"FREMONT, Calif., May 07, 2026--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent business accomplishments, and reaffirmed financial guidance for the full year 2026.","length":330,"tagName":"p"},{"type":"text","content":"First Quarter and Recent Strategic and Operational Highlights","length":61,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Secured Milestone Medicare Coverage for Lung Cancer: Received Medicare coverage approval in the first quarter for the surveillance of cancer recurrence in lung cancer patients for Stage I to III non-small cell lung cancer (NSCLC). This marks the Company's second major coverage decision in six months, alongside breast cancer.","length":330,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced Early Access Launch of Real-Time Variant Tracker™: Launched a pioneering new feature for NeXT Personal® that empow...